S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Laser breakthrough could send stock soaring 2,467% (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
66,000% upside on tiny biotech? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Laser breakthrough could send stock soaring 2,467% (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
66,000% upside on tiny biotech? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Laser breakthrough could send stock soaring 2,467% (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
66,000% upside on tiny biotech? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Laser breakthrough could send stock soaring 2,467% (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
66,000% upside on tiny biotech? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
NASDAQ:TSRO

Tesaro (TSRO) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$74.94
$74.97
50-Day Range
N/A
52-Week Range
$23.41
$75.16
Volume
1.19 million shs
Average Volume
1.97 million shs
Market Capitalization
$4.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TSRO stock logo

About Tesaro (NASDAQ:TSRO) Stock

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.


TSRO Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
See More Headlines
Receive TSRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tesaro and its competitors with MarketBeat's FREE daily newsletter.

TSRO Company Calendar

Last Earnings
8/02/2018
Today
9/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:TSRO
CUSIP
88156910
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-496,120,000.00
Net Margins
-295.67%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$223.33 million
Book Value
$4.58 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.13 billion
Optionable
Optionable
Beta
0.38
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Leon O. Moulder Jr. (Age 62)
    Co-Founder, CEO & Director
  • Dr. Mary Lynne Hedley Ph.D. (Age 56)
    Co-Founder, Pres, COO & Director
  • Mr. Timothy R. Pearson (Age 51)
    Exec. VP & CFO
  • Dr. Martin H. Huber Jr. (Age 59)
    Sr. VP & Chief Medical Officer
  • Mr. Orlando Oliveira (Age 43)
    Sr. VP & GM of International













TSRO Stock - Frequently Asked Questions

How were Tesaro's earnings last quarter?

Tesaro, Inc. (NASDAQ:TSRO) released its quarterly earnings data on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.66) by $0.38. The biopharmaceutical company had revenue of $57.21 million for the quarter, compared to the consensus estimate of $65.50 million. Tesaro had a negative net margin of 295.67% and a negative trailing twelve-month return on equity of 1,209.72%. Tesaro's revenue for the quarter was up 94.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.82) earnings per share.

What other stocks do shareholders of Tesaro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tesaro investors own include NVIDIA (NVDA), Clovis Oncology (CLVS), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Intercept Pharmaceuticals (ICPT), Incyte (INCY) and Regeneron Pharmaceuticals (REGN).

What is Tesaro's stock symbol?

Tesaro trades on the NASDAQ under the ticker symbol "TSRO."

What is Tesaro's stock price today?

One share of TSRO stock can currently be purchased for approximately $74.96.

How much money does Tesaro make?

Tesaro (NASDAQ:TSRO) has a market capitalization of $4.13 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis.

How can I contact Tesaro?

Tesaro's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.tesarobio.com. The biopharmaceutical company can be reached via phone at 339-970-0900.

This page (NASDAQ:TSRO) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -